Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases

Luminal A breast cancer is the most common breast cancer subtype which is usually treated with selective estrogen receptor modulators (SERMS) like tamoxifen. Nevertheless, one third of estrogen receptor positive breast cancer patients initially do not respond to endocrine therapy and about 40% of lu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Sommer, Ann-Katrin, Hermawan, Adam, Mickler, Frauke Martina, Ljepoja, Bojan, Knyazev, Pjotr, Bräuchle, Christoph, Ullrich, Axel, Wagner, Ernst, Roidl, Andreas
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2016
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5226596/
https://ncbi.nlm.nih.gov/pubmed/27409163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10459
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge